Study to Assess the Safety and Tolerability of PF-07220060 in Combination With PF-07104091 in Participants With Breast Cancers or Solid Tumors and to Assess the Safety and Tolerability of PF-07220060 and PF-07104091 in Combination With Endocrine Therapy in Participants With Breast Cancer.

Study to Assess the Safety and Tolerability of PF-07220060 in Combination With PF-07104091 in Participants With Breast Cancers or Solid Tumors and to Assess the Safety and Tolerability of PF-07220060 and PF-07104091 in Combination With Endocrine Therapy in Participants With Breast Cancer.
Conditions:   Breast Cancer;   Solid Tumors
Interventions:   Drug: PF-07220060 + PF-07104091 combination dose escalation;   Drug: PF-07104091 + PF-07220060 + fulvestrant dose expansion;   Drug: PF-07104091 + PF-07220060 + letrozole dose expansion
Sponsor:   Pfizer
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 1, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments
Free Clinical Trial Updates

    #1 Best New Product in 2019
    Headache Relief Shampoo Banner Ad
    Search For Clinical Trials
    CLOSE
    Please click to geolocate button to change this value.
    SEARCHRESET
    Featured Research Centers